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We investigated patients with systemic lupus erythematosus with the objective of assessing
whether early damage accrued in systemic lupus erythematosus as measured by the SLICC/
ACR Damage Index predicts mortality in lupus patients that have been followed prospectively
in a single center. Patients with systemic lupus erythematosus from Aga Khan University
hospital presenting between 1992 and 2007 were included. This enabled all patients to be
potentially followed for at least 10 years. Yearly SLICC/ACR Damage Index scores were
determined for each patient. Early damage was defined as a score 1, and no damage as a
score of 0 at the initial assessment. Kaplan–Meier and Log rank tests were used to compare
the survival experience between those with and without damage, with all patients being
assessed at 10 years. In this inception cohort 198 patients were identified and were followed
for 10 years. Of these, 47 (23.7%) patients had a SLICC/ACR Damage Index score of 0 (no
damage) while 151 patients (76.3%) had at least one SLICC/ACR Damage Index item scored
(early damage). Mean renal damage score at 1, 5 and 10 years was 0.16, 0.34 and 0.67, respec-
tively. Of lupus patients who exhibited renal damage at their first SLICC/ACR Damage Index
assessment, 31% died within 10 years of their illness as compared with only 13% who had no
early renal damage (p< 0.003). Mean renal damage score at 1 year after diagnosis was a
significant predictor of death within 10 years of diagnosis (p< 0.002). Lupus (2010) 19,
1573–1578.
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Introduction
Systemic lupus erythematosus (SLE) is still a signif-
icant cause of morbidity and increased mortality.1
However, relevant changes in the spectrum of lupus
complications, both in quantitative and qualitative
terms, have occurred in the past decades. Review of
recent literature suggests remarkable improvement
in prognosis of patients with SLE in the western
world over the past few decades, from a 5-year sur-
vival rate of only 50% in the 1950s2 to a 10-year
survival rate of nearly 90% in the last decade.3,4
However, despite the overall improvement in sur-
vival, the incidence of SLE has nearly tripled and
10–25% of patients still succumb within 10 years of
disease onset.5 Severe organ involvement related to
SLE itself and infections remain common causes of
mortality.6 Poor survival of SLE is still reported in
certain ethnic groups such as Asians,6,7 Black
Caribbeans8 and Hispanics.9
The SLICC/ACR Damage Index was developed
in 1992.10 It was created to assess an ongoing reﬂec-
tion of disease activity in patients with SLE and
hence to measure irreversible damage resulting
from SLE disease activity and its treatment. Since
1992, a number of investigators have used the
Damage Index in their clinical studies. The new
concept of irreversible organ damage in SLE has
been deﬁned as irreversible changes in organ or
systems accrued during the course of lupus,
although not necessarily caused by SLE (i.e. could
be the result of treatment or concurrent condi-
tions), and persisting for at least 6months.11
Organ damage occurs in 50% of patients within
5 years of diagnosis of SLE,12,13 and is associated
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with increased mortality.14 Risk factors for damage
include older age at diagnosis,12–14 longer duration
of SLE,12 African-Caribbean or Asian ethnicity,14
high disease activity at diagnosis,12,13 and greater
overall activity during the disease course.15,16
Although SLE is not an uncommon disease in
South Asia, no data exist about organ damage
and its impact on patient survival in Pakistan.
This study was therefore conducted to assess
organ damage accrued in SLE, as assessed by the
SLICC/ACR Damage Index, and its impact on the
survival of these patients.
Methods
Patients
An inception cohort of all of our patients with SLE
in whom the diagnosis was established at least
10 years prior to November 2007, and who had sub-
sequently attended a specialist clinic, was studied.
At each outpatient consultation, detailed clinical
and serological information was recorded. Case
note documentation, assessment of disease activity,
generation of damage scores and deﬁnition of dis-
ease ﬂares were standardized, and patients were
seen by the same group of nephrologists and rheu-
matologists throughout. Patients were followed-up
prospectively at regular intervals of 6–8weeks.
More frequent follow-up was arranged for patients
who had severe organ involvement, who had just
had a disease ﬂare or who were receiving intensive
immunosuppression. Damage scores (DS) in each
system and mortality data were recorded during the
disease course of our patients. Disease activity was
measured by the SLEDAI.17 SLEDAI scores were
obtained at the time of ﬁrst presentation and sub-
sequent visits. Assessment of organ damage was
made using the SLICC/ACR index.10 Damage
was deﬁned as irreversible impairment that was pre-
sent after the diagnosis of SLE and persistent for
more than 6months, irrespective of whether it was
related to disease activity or treatment. For patients
whose SLE was diagnosed before 1998, DS were
obtained retrospectively. After 1998, the Damage
Index was scored yearly. The total cumulative DS
were summated for each patient at the end of the
study. In case of a lethal outcome, the last DS was
determined 6months before death. The weighted
total DS was calculated by multiplying the neuro-
psychiatric, renal and cardiovascular DS by four,
the ocular, pulmonary, peripheral vascular and
malignancy DS by three, and the gastrointestinal
and musculoskeletal DS by two, resulting in a
potential maximum of 133 points.11 Every patient
was carefully reviewed for evidence of having had a
severe outcome within 10 years after diagnosis,
deﬁned as either death or end-stage renal failure
(ESRF) necessitating dialysis. If a patient had
moved and had not been attending our outpatient
clinic, attempts were made to contact her/him and
their physicians to obtain the necessary data.
Statistical analysis
Statistical package for social science (SPSS) version
13.0 was used for data analysis. Results are pre-
sented as mean standard deviation for quantita-
tive variables and number (percentages) for
qualitative variables. Univariate analysis was
performed by using independent sample t-test to
compare the means, and diﬀerences in proportion
were assessed by using Pearson Chi-Square test.
Logistic regression analysis was used to identify
the independent risk factors for damages. The
probability curves of survival were calculated
according to the Kaplan–Meier method and com-
pared by the log rank test. Multivariate analysis
was performed by using Cox Proportional Hazard
model, to identify the independent risk factor for
poor survival. All of the variables selected for the
building of the multivariate model have biologically
important p-values of less than 0.25 in univariate
analysis. A p-value less than 0.05 (two sided) was
considered as statistically signiﬁcant.
Results
The group studied comprised 198 patients,
174 females and 24 males. A total of 147 patients
fulﬁlled the ARA criteria18 for diagnosis of SLE
(4/11 criteria). The remaining 49 patients fulﬁlled
three of the 11 ARA criteria, and were diagnosed
on the basis of a high clinical suspicion of the dis-
ease, renal or skin biopsy suggestive of SLE, posi-
tive anti-dsDNA antibodies and clinical response to
treatment. Mean age at presentation was 31 years
(range 14–76 years). Mean duration of follow-up
was 34months (range 4–179months). Mean
SLEDAI score at disease presentation was
11.7 0.40 (range 4–33).
Cutaneous manifestations of SLE (46%) were
relatively less common in our sample. Malar rash
was present in 56 patients (29%), discoid lupus
in 27 (14%), photosensitivity in 12 patients (6%)
and alopecia in 44 patients (22%). A total of 105
patients (53%) were febrile at the time of presenta-
tion. There were variable occurrences of renal,
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central nervous system (CNS), serosal, hematolog-
ical and articular involvement. Of the patients,
33% (n¼ 65) had renal involvement at presenta-
tion. Of these 65 patients, 50% had raised
serum creatinine at the time of presentation
(normal 0.8–1.3mg/dl), 74% had proteinuria
detectable on urine dipstick, and 55% had nephri-
tic-range proteinuria at presentation. Renal biopsy
ﬁndings revealed that 64% of the patients had
WHO class 4, 17% had class 5, 14% had class 3,
and 5% had class 2 histological ﬁndings. Serosal
involvement was noted in 44 (22%) patients.
Pleural eﬀusion was seen in 33 patients (17%)
and pericardial eﬀusion in 18 patients (9%).
Articular involvement was noted in 76 patients
(38%). Regarding hematological parameters, 26%
of patients had thrombocytopenia, 22% had leuco-
penia and 54% had signiﬁcant lymphopenia. Some
5% of the patients presented with pancytopenia
(n¼ 9). CNS involvement was noted in 26% of
patients (n¼ 52). Of these 52 patients, 15% pre-
sented with frank psychosis and 14% had seizures
at some stage during the course of illness. We found
that 86% of the patients were ANA positive
(n¼ 168). Anti-dsDNA test results were positive
in 74% of patients (n¼ 146).
Regarding immunosuppressive treatment, 178
(90%) were treated with oral corticosteroids, and
39 (20%) received intravenous pulse methylprednis-
olone therapy. An initial high-dose regimen (oral
prednisone 1mg/kg/day or intravenous pulse
methylprednisolone therapy), mainly indicated for
renal, CNS and hematological disease, was received
by 52% of patients. The cumulative numbers and
percentages of patients who received azathioprine
and cyclophosphamide were 81 (41%) and 27
(14%), respectively. Two patients received chlor-
ambucil. Cyclosporin was used in only seven
patients.
Of our patients, 76% had organ damage at the
time of data analysis; 30% had a SLICC score of 1,
32% of patients had a SLICC score of 2, and
14.5% had SLICC score of 3 or more. The kidneys
were the commonest organ being damaged
(37.5%), followed by the CNS (28%), skin
(28.5%) and musculoskeletal systems (25.5%).
Median SLICC score of the whole cohort was
1 (range 0–5) and for those who had damage,
median SLICC score was 2 (range 1–5). No signif-
icant diﬀerence in DS could be demonstrated
between female and male patients (p< 0.84). Age
at disease onset and disease duration did not cor-
relate with SLICC scores (p< 0.42 and p< 0.02,
respectively).
Univariate and multivariate analysis were per-
formed to study the predictive factors for damage.
Alopecia (p< 0.000), discoid lesions (p< 0.01), sei-
zures (p< 0.048), renal disease (p< 0.000), and
musculoskeletal system (p< 0.014) involvement
were univariately associated with damage.
Logistic regression (multivariate analysis) with out-
come being damage, and the prevalence of other
clinical features, auto-antibodies, demographic
data (e.g. age and sex) and drug treatment being
predictor variables, showed that only alopecia
(p< 0.009) and renal disease (p< 0.002) were inde-
pendent predictors for damage (Table 1).
As renal damage was the most commonly seen
organ damage in our patients a separate logistic
regression analysis was performed, with outcome
being renal damage and other clinical variables as
described above being predictors. It was found that
anemia at onset (p¼ 0.018) and malar rash
(p¼ 0.031) were independent risk factors for renal
damage.
Twenty-seven patients died within 1 year; how-
ever, damage could be scored at 1 year after diag-
nosis in all 198 patients. At 5 years a further
15 patients had died. At 10 years four more patients
had died, and the DS could be determined in only
142 patients. Thus, by the end of the study, l0 years
after establishing the diagnosis of SLE, 46 patients
had died while 12 patients had developed ESRF.
Mean renal DS at 1 year was 0.16 (15%), and it
progressively increased to 0.34 (29%) and 0.67
(37%) at 5 and 10 year time intervals, respectively.
Table 2 shows that although mean DS in neuropsy-
chiatry was signiﬁcant at 1 year and it did show rise
in cumulative DS at 5 and 10 years, it did not how-
ever predict mortality (p¼ 0.067). The mean renal
DS at 1 year in surviving patients was signiﬁcantly
lower compared with those who had died
(p< 0.002). Survival at 10 years in patients with
early renal involvement was less than 60% com-
pared with 85% in those with normal renal func-
tion (Figure 1). Similarly, the mean renal DS at
Table 1 Multivariate analysis of predictors for damage in our
cohort of patients
95% confidence interval (CI)
Variables
Significance
(p-value) Lower CI Upper CI
Serum Creatinine 0.002 2.258 44.158
Seizures 0.067 0.902 19.535
Alopecia 0.009 1.950 115.317
Pleuritis 0.083 0.836 18.203
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1 year of those patients developing ESRF was sig-
niﬁcantly higher than the corresponding mean in
patients with no ESRF up to 10 years after diagno-
sis (p¼ 0.008). Table 2 outlines the signiﬁcant dif-
ferences in renal, neuropsychiatry, pulmonary,
total and weighted DS at 1, 5 and l0 years.
Discussion
During the last decade, the emergence of better
techniques for diagnosis, the availability of novel
and more reﬁned immunosuppressive agents and
hence better disease management have signiﬁcantly
improved the survival of patients with SLE.
However, research has shown that majority of
patients with SLE sustain permanent damage in
one or more organs because of the disease itself,
its treatment, or co-morbid processes.13,14,19
Moreover, by deﬁnition, the SLICC/ACR
Damage Index scores cumulative damage since
the onset of SLE and are therefore likely to increase
with disease progression. In this study the mean
renal DS 1 year after diagnosis signiﬁcantly pre-
dicted death. The relevant item in those who died
was elevated serum creatinine. The mean renal DS
at 1 year also signiﬁcantly correlated with the devel-
opment of ESRF. These ﬁndings correspond with
the fact that reduced glomerular ﬁltration rate or
proteinuria is a predictor for poor renal out-
come.20,21 Moreover, a signiﬁcantly higher renal
DS after 5 and 10 years in patients with ESRF
appears to corroborate these ﬁndings. These ﬁnd-
ings, in accordance with the literature,20–22 demon-
strate the prognostic validity of the renal item of
the SLICC/ACR Damage Index. Despite the fact
that interstitial lung disease22 and pulmonary
hypertension in SLE23 are known to increase mor-
tality, mean pulmonary DS at 1, 5 and 10 years
after diagnosis did not prove statistically signiﬁcant
to predict death. Other organ DS, for example in
the neuropsychiatric or the cardiovascular systems,
and the total DS did not show prognostic value in
the present study.
Our report is the ﬁrst in our region to describe
the prognostic validity of the SLICC/ACR Damage
Index in a Pakistani population. Moreover, com-
pared with Caucasians and Afro-Caribbeans,24–26
signiﬁcantly higher mean renal DS at 5 and
10 years were found in our population. We also
found signiﬁcantly lower occurrence of ESRF in
our population, compared with other ethnic
groups.27 Moreover, compared to Caucasian and
Afro-Caribbean patients, a lower mean neuropsy-
chiatric DS 5 years after diagnosis was found.
We noted a rather low prevalence of diﬀerent
organ involvement, e.g. 13.2% neuropsychiatric
disease at 5 years and 28% at 10 years after diagno-
sis compared with ﬁgures of CNS involvement of
12–59% reported by other groups.28 However, it is
worth mentioning that SLICC/ACR Damage
Index scores only those items likely to be relevant
to outcome. Neurological problems such as
migraine, a frequent neuropsychiatric ﬁnding in
patients with SLE, will not score as damage. In
addition, a symptom/ﬁnding has to be present con-
tinuously for at least 6months to score. Subtle
changes such as cognitive impairment will only be
scored when they are clinically overt, and hence
impairment demonstrable with detailed neuropsy-
chiatric testing or magnetic resonance imaging will
Table 2 Progression of damage scores (DS) and cumulative
prevalence of damage over time
DS (mean) Cumulative prevalence of damage at
1 year 5 years 10 years
Total DS (unweighted) 0.57 1.13 1.83
Weighted DS (Total) 1.47 3.10 5.51
Renal DS 0.16; 15% 0.34; 29% 0.67; 37%
Neuropsychiatry DS 0.04; 7.5% 0.12; 13.2% 0.27; 28%
Pulmonary DS 0.02; 2.5% 0.02; 3.9% 0.05; 4%
GI DS 0.02; 2% 0.02; 2% 0.02; 2%
Cardiovascular DS 0.01; 2.5% 0.03; 3.7% 0.04; 4.5%
Musculoskeletal DS 0.15; 14% 0.2; 20% 0.26; 25%
Skin DS 0.14; 13% 0.28; 23% 0.34; 28%
Gonadal DS 0.00; 0% 0.00; 0% 0.00; 0%
Ocular DS 0.00; 0% 0.02; 2.4% 0.02; 2.4%
Peripheral 0.03 0.08 0.12
Endocrine/Malignancy
DS
0.00; 0% 0.02; 2.4% 0.04; 4%
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Figure 1 Probability of survival in patients with and without
renal damage.
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not be counted as damage in a patient who seems
clinically unaﬀected. This is probably because
assessment by the SLICC/ACR Damage Index is
designed to be feasible for all physicians to com-
plete, being based on clinical examination and
simple investigations (urinalysis, creatinine, X-ray
of the chest).
The percentage of early organ damage and the
mortality rate during the initial phase of disease is
much higher in our cohort as compared with that of
other recently reported major cohorts.14 However,
direct comparison of the survival rates and organ
DS among diﬀerent studies is not easy because of
the discrepancies in patient selection and treatment
protocols. Most published survival studies of SLE
have been retrospective, and selection bias and
incompleteness of medical records are major
ﬂaws. Moreover, the proportion of patients with
severe organ manifestations included in diﬀerent
series as a result of referral patterns may also inﬂu-
ence the survival rates. However, we believe that
delayed referrals to tertiary care hospitals, non-
availability of immunosuppressive agents in the
past, poor socioeconomic status and non-compli-
ance are some of the possible factors responsible
for high organ damage and mortality rate seen
during the initial phase of the disease in our cohort.
We also believe that our population has an ele-
vated risk of progression similar to African-
American and Hispanic patient, and given the
results of multivariate analyses, much of the
poorer prognosis of our patients may be due to
socioeconomic rather than biological or genetic fac-
tors. Indeed, the relative importance of genetic fac-
tors may be ampliﬁed by environmental factors
that are associated with poverty. It has been postu-
lated that diﬀerences in severity of SLE may be
related to diﬀerent genotypes.29 As many genes
have been identiﬁed, it may well be that lupus in
Pakistan has a diﬀerent genetic etiology, responsi-
ble for varying disease susceptibility and expres-
sion. Furthermore, Pakistan has a very high rate
of consanguineous marriages. In Pakistan, over
60% of marriages are between ﬁrst and second cou-
sins,30,31 which will lead to a conservation of certain
genotypes causing the disease, and impede their
transmission to other races. Further studies will
be required to explain the contributing role of envi-
ronmental and genetic factors in order to explain
ethnic diﬀerence in lupus susceptibility and its
expression in our local population.
In conclusion, in this study, renal DS at 1, 5 and
10 years after diagnosis were signiﬁcantly higher
than other organ DS in our patient population.
Severe outcome in terms of ESRF and mortality
in patients with SLE correlates signiﬁcantly with a
higher mean renal DS at 1 year.
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